COLLPLANT BIOTECH. IS-01 (CPT) - Net Assets
Based on the latest financial reports, COLLPLANT BIOTECH. IS-01 (CPT) has net assets worth €6.08 Million EUR (≈ $7.11 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€10.79 Million ≈ $12.61 Million USD) and total liabilities (€4.70 Million ≈ $5.50 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check CPT asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €6.08 Million |
| % of Total Assets | 56.38% |
| Annual Growth Rate | -39.41% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 17.65 |
COLLPLANT BIOTECH. IS-01 - Net Assets Trend (2021–2025)
This chart illustrates how COLLPLANT BIOTECH. IS-01's net assets have evolved over time, based on quarterly financial data. Also explore COLLPLANT BIOTECH. IS-01 balance sheet assets for the complete picture of this company's asset base.
Annual Net Assets for COLLPLANT BIOTECH. IS-01 (2021–2025)
The table below shows the annual net assets of COLLPLANT BIOTECH. IS-01 from 2021 to 2025. For live valuation and market cap data, see CPT company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €6.08 Million ≈ $7.11 Million |
-54.84% |
| 2024-12-31 | €13.46 Million ≈ $15.74 Million |
-52.49% |
| 2023-12-31 | €28.34 Million ≈ $33.13 Million |
-12.21% |
| 2022-12-31 | €32.28 Million ≈ $37.74 Million |
-28.46% |
| 2021-12-31 | €45.12 Million ≈ $52.75 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to COLLPLANT BIOTECH. IS-01's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 5204200000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €130.92 Million | 2152.94% |
| Total Equity | €6.08 Million | 100.00% |
COLLPLANT BIOTECH. IS-01 Competitors by Market Cap
The table below lists competitors of COLLPLANT BIOTECH. IS-01 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Anglo Asian Mining Plc
LSE:AAZ
|
$4.34 Million |
|
Foresight Solar Fund Ltd
LSE:FSFL
|
$4.34 Million |
|
Gratomic Inc
V:GRAT
|
$4.35 Million |
|
Vectus Biosystems Ltd
AU:VBS
|
$4.35 Million |
|
Binani Industries Limited
NSE:BINANIIND
|
$4.34 Million |
|
Kingman Minerals Ltd
V:KGS
|
$4.33 Million |
|
MOVIE GAMES S.A. ZY1
F:2LH
|
$4.33 Million |
|
Munic SA
PA:ALMUN
|
$4.33 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in COLLPLANT BIOTECH. IS-01's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 13,465,000 to 6,081,000, a change of -7,384,000 (-54.8%).
- Net loss of 11,489,000 reduced equity.
- New share issuances of 3,102,000 increased equity.
- Other factors increased equity by 1,003,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-11.49 Million | -188.93% |
| Share Issuances | €3.10 Million | +51.01% |
| Other Changes | €1.00 Million | +16.49% |
| Total Change | €- | -54.84% |
Book Value vs Market Value Analysis
This analysis compares COLLPLANT BIOTECH. IS-01's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.56x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.06x to 0.56x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €4.19 | €0.27 | x |
| 2022-12-31 | €2.89 | €0.27 | x |
| 2023-12-31 | €2.47 | €0.27 | x |
| 2024-12-31 | €1.18 | €0.27 | x |
| 2025-12-31 | €0.48 | €0.27 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently COLLPLANT BIOTECH. IS-01 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -188.93%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -484.56%
- • Asset Turnover: 0.22x
- • Equity Multiplier: 1.77x
- Recent ROE (-188.93%) is below the historical average (-77.79%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 0.53% | 1.52% | 0.31x | 1.14x | €-4.28 Million |
| 2022 | -52.43% | -5660.54% | 0.01x | 1.17x | €-20.15 Million |
| 2023 | -24.77% | -64.05% | 0.32x | 1.20x | €-9.85 Million |
| 2024 | -123.35% | -3225.05% | 0.03x | 1.39x | €-17.96 Million |
| 2025 | -188.93% | -484.56% | 0.22x | 1.77x | €-12.10 Million |
Industry Comparison
This section compares COLLPLANT BIOTECH. IS-01's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $355,224,390
- Average return on equity (ROE) among peers: -60.76%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| COLLPLANT BIOTECH. IS-01 (CPT) | €6.08 Million | 0.53% | 0.77x | $4.34 Million |
| PROQR THERAPEUTICS EO-04 (0PQ) | $66.68 Million | -96.62% | 1.57x | $142.34 Million |
| TIZIANA LIFE SCIENCES LTD (0RP) | $3.94 Million | -301.40% | 1.87x | $161.62 Million |
| Theravance Biopharma Inc (0TB) | $289.79 Million | -81.80% | 0.17x | $823.46 Million |
| I-MAB SPONS.ADS/1 -0001 (0VY) | $230.94 Million | -20.03% | 0.13x | $205.51 Million |
| PreveCeutical Medical Inc (18H) | $-4.49 Million | 0.00% | 0.00x | $3.34 Million |
| Argen-X (1AE) | $1.36 Billion | -38.77% | 0.36x | $41.67 Billion |
| WAVE LIFE SCIENCES LTD. (1U5) | $-45.09 Million | 0.00% | 0.00x | $1.14 Billion |
| BIOCURE TECHNOLOGY INC. (1WH) | $-852.32K | 0.00% | 0.00x | $960.84K |
| ZAI LAB LTD0000006 (1ZLB) | $1.38 Billion | -51.05% | 0.17x | $1.82 Billion |
| BioNTech SE (22UA) | $267.00 Million | -17.98% | 1.45x | $20.05 Billion |
About COLLPLANT BIOTECH. IS-01
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on its recombinant human collagen (rhCollagen) that is produced using its proprietary technology. The company offers regenerative dermal a… Read more